アスペルギルス症市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、競合別セグメント、2020-2030F

アスペルギルス症の世界市場は、2024年に46億3,000万米ドルと評価され、2030年には58億7,000万米ドルに達すると予測され、予測期間中の年間平均成長率（CAGR）は4.02％で成長すると予測されています。

同市場は、アスペルギルス関連真菌感染症がもたらす課題への対応に注力するヘルスケア分野に不可欠な市場です。アスペルギルス症はアスペルギルス種によって引き起こされる疾患群で、侵襲性アスペルギルス症は最も重篤な病型であり、臓器移植を受けた患者や化学療法を受けている患者など、免疫力が低下している人が主に罹患します。同市場は、これらの感染症を管理・予防するための幅広い診断・治療・予防ソリューションを包含しています。

市場成長の主な要因は、HIV/AIDSの罹患率の上昇、臓器移植、免疫抑制療法の普及などにより、免疫不全患者が増加していることです。このため、早期発見と迅速な治療を可能にするPCRアッセイ、抗原検査、CTスキャンなどの画像診断技術を含む高度な診断ツールに対する需要が急増しています。

主な市場促進要因

免疫不全患者の増加

主な市場課題

認知度の低下と過小診断

主な市場動向

免疫調節療法

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のアスペルギルス症市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別（慢性肺アスペルギルス症、アレルギー性気管支肺アスペルギルス症（ABPA）、侵襲性アスペルギルス症）
  • 薬剤の種類別（イサブコナゾール、ボリコナゾール、アムホテリシンB、イトラコナゾール、コルチコステロイド、ポサコナゾール、その他）
  • 投与経路（経口、静脈内）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • タイプ別
  • 薬剤の種類別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域のアスペルギルス症市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 薬剤の種類別
  • 投与経路別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のアスペルギルス症市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のアスペルギルス症市場展望

• 市場規模・予測
• 市場シェア・予測
  • タイプ
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のアスペルギルス症市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのアスペルギルス症市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のアスペルギルス症市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Pfizer Inc.
• Therma Fisher Scientific
• Rewine Pharmaceuticals
• Teva Pharmaceuticals
• Eugia Pharma
• krishlar Pharmaceuticals
• Merck KGA
• Aozeal
• Hikma
• Xellia Pharmaceuticals

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Aspergillosis Market was valued at USD 4.63 billion in 2024 and is projected to reach USD 5.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.02% during the forecast period. This market is an integral part of the healthcare sector, focusing on addressing the challenges posed by Aspergillus-related fungal infections. Aspergillosis is a group of diseases caused by the Aspergillus species, with invasive aspergillosis being the most severe form, predominantly affecting individuals with weakened immune systems, such as organ transplant recipients and patients undergoing chemotherapy. The market encompasses a broad range of diagnostic, therapeutic, and preventive solutions designed to manage and combat these infections.

A primary driver of market growth is the increasing prevalence of immunocompromised individuals, fueled by rising rates of HIV/AIDS, organ transplants, and the expanded use of immunosuppressive therapies. This has led to a surge in demand for advanced diagnostic tools, including PCR assays, antigen testing, and imaging techniques such as CT scans, which enable early detection and prompt treatment.

Key Market Drivers

Rising Incidence of Immunocompromised Patients

The growth of the global aspergillosis market is significantly influenced by the rising number of immunocompromised patients. Individuals with conditions such as HIV/AIDS, those undergoing organ transplants, and patients receiving immunosuppressive therapies are particularly vulnerable to Aspergillus-related infections. In 2023, approximately 39.9 million people globally were living with HIV, with 1.3 million new infections reported that year. In the United States, an estimated 3% of adults are immunocompromised due to immune-affecting conditions or treatments. Additionally, 172,409 organ transplants were conducted worldwide in 2023, a 9.5% increase from the previous year. These statistics underscore the growing population of immunocompromised individuals, driving demand for diagnostics and treatments for infections like aspergillosis.

Studies also show that immunocompromised patients face a heightened risk of severe infections, including those caused by SARS-CoV-2, highlighting the need for specialized care and preventive strategies. This trend emphasizes the need for tailored therapies and enhanced healthcare infrastructure to meet the unique needs of these patients, further propelling market expansion in the aspergillosis sector.

Key Market Challenges

Limited Awareness and Underdiagnosis

A significant challenge faced by the global aspergillosis market is the lack of awareness and underdiagnosis of Aspergillus-related infections. Despite the severe health risks associated with aspergillosis, it remains relatively unknown outside specialized medical circles. Many healthcare professionals, and the general public, are unfamiliar with the symptoms and risks of this fungal infection, which can often mimic other respiratory conditions, leading to misdiagnosis or delays in diagnosis. This lack of timely diagnosis can result in suboptimal or incorrect treatment, affecting patient outcomes and hindering market growth.

Furthermore, underdiagnosis-an issue stemming from limited awareness-poses a serious concern. Without early intervention, aspergillosis can progress from a treatable condition to a life-threatening disease, particularly in immunocompromised individuals. The absence of widespread educational campaigns means that high-risk populations, such as organ transplant recipients or those undergoing immunosuppressive therapies, may not receive proper screening or information. These challenges create missed opportunities for market development and the timely delivery of critical treatments.

Key Market Trends

Immunomodulatory Therapies

Immunomodulatory therapies are emerging as a key growth driver in the global aspergillosis market. These therapies, designed to modulate and enhance the immune response, offer a promising adjunctive approach to managing aspergillosis, particularly in immunocompromised individuals. For patients with weakened immune systems-such as transplant recipients, chemotherapy patients, and those with underlying immunodeficiencies-the risk of invasive aspergillosis is significantly elevated. Immunomodulatory agents like granulocyte colony-stimulating factors (G-CSF) and interferon-gamma are being studied for their potential to stimulate the immune system and help patients better combat fungal infections.

Clinical trials have demonstrated that immunomodulatory therapies, when used alongside traditional antifungal treatments, can significantly improve patient outcomes by enhancing immune function. These therapies not only aid in controlling current infections but also reduce the risk of recurrence, which is a common concern in aspergillosis management. As the benefits of immunomodulatory therapies become increasingly recognized, healthcare providers are incorporating them into treatment regimens, stimulating further market growth as pharmaceutical companies invest in developing targeted therapies tailored to the needs of aspergillosis patients.

Key Market Players

• Pfizer Inc
• Therma Fisher Scientific
• Rewine Pharmaceuticals
• Teva Pharmaceuticals
• Eugia Pharma
• krishlar Pharmaceuticals
• Merck KGA
• Aozeal
• Hikma
• Xellia Pharmaceuticals

Report Scope:

In this report, the Global Aspergillosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Aspergillosis Market, By Type:

• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Invasive Aspergillosis

Aspergillosis Market, By Drug Type:

• Isavuconazole
• Voriconazole
• Amphotericin-B
• Itraconazole
• Corticosteroids
• Posaconazole
• Others

Aspergillosis Market, By Route of Administration:

• Oral
• Intravenous

Aspergillosis Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Aspergillosis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Aspergillosis Market.

Available Customizations:

Global Aspergillosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Aspergillosis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Invasive Aspergillosis)
  • 4.2.2. By Drug Type (Isavuconazole, Voriconazole, Amphotericin-B, Itraconazole, Corticosteroids, Posaconazole, Others)
  • 4.2.3. By Route of Administration (Oral, Intravenous)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Type
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Aspergillosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Type
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Aspergillosis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Type
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Aspergillosis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Type
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Aspergillosis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Type
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Aspergillosis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Type
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Aspergillosis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Type
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Aspergillosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Aspergillosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Aspergillosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Aspergillosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Aspergillosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Type
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Aspergillosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Type
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Aspergillosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Aspergillosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Aspergillosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Aspergillosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Aspergillosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Aspergillosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Aspergillosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Aspergillosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Aspergillosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Aspergillosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Aspergillosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Aspergillosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Aspergillosis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Pfizer Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Therma Fisher Scientific
• 14.3. Rewine Pharmaceuticals
• 14.4. Teva Pharmaceuticals
• 14.5. Eugia Pharma
• 14.6. krishlar Pharmaceuticals
• 14.7. Merck KGA
• 14.8. Aozeal
• 14.9. Hikma
• 14.10. Xellia Pharmaceuticals

15. Strategic Recommendations

16. About Us & Disclaimer